#AseBioInterview | This has been the development process of the first vaccine against Epiz... 17/07/2024 Healthcare Innovative drugs Agrifood Animal health "Currently, the outbreak of EHDV serotype 8 is generating great alarm due to its epidemic potential and the absence of a... AseBio - Zendal
ORYZON receives “Decision to grant” for two important patents for vafidemstat in Japan 08/07/2024 Healthcare Innovative drugs For the treatment of Borderline Personality Disorder (BPD) and Attention Deficit Hyperactivity disorder (ADHD). Partners - Oryzon Genomics
Juan Basterra (Mikrobiomik) | "In the last 10 years, decisive steps have been taken to und... 27/06/2024 Healthcare Drug discovery Innovative drugs Mikrobiomik is working to become the first company globally to market the first biological drug based on gut microbiota... AseBio - Mikrobiomik
Overcoming Challenges in the Current Biotech Landscape 24/06/2024 Biotech entrepreneurs have experienced a demanding drug development environment in the last 24 months. To succeed... Partners
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Miramoon Pharma Receives Orphan Drug Designation for MP-004 28/05/2024 Healthcare Access to innovation Rare diseases Innovative drugs Orphan Drug Designation is a special status granted by the FDA to drugs that are intended to treat rare diseases or... Partners - Miramoon Pharma
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for... 24/05/2024 Healthcare Access to innovation Innovative drugs Advanced therapies it is a medicine to improve progression-free survival and overall survival in patients with metastatic pancreatic... Partners
Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate... 21/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies ApTOLL shows potential for slowing the progression of multiple sclerosis (MS) in preclinical animal studies. Partners - AptaTargets
